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KA THERINE S. HA USER, MD 
Serial human placental lactogen (hPL) determinations were 
performed on 806 women with normal and abnormal preg-
nancies late in the pregnancy. These results were not re-
ported to the clinicians involved. for the study population 
as a whole, low hPL levels did not effectively predict those 
adverse perinatal outcome variables evaluated. further 
analysis revealed that this was true both for the normal and 
abnormal pregnancy groups. Our data do not support the 
routine use of antepartum hPL screening. as advocated by 
others, as a means of improving perinatal outcome. In cer-
tain at-risk patients, there was an association between low 
hPL values and the presence of 1 or more of the adverse 
outcome variables. However, these patients had been rec-
ognized clinically as having fetuses in jeopardy. 
The clinical utility of serum human placental lactogen 
(hPL) determinations in improving perinatal outcome 
has not been clearly defined. Certain reports suggest 
that this test may be of value in monitoring abnormal 
pregnancies,I.2 while others are less hopeful in tHis re-
gard.3 •• Low hPL levels have been reported by some to 
correlate with adverse fetal/neonatal outcome in clini-
cally normal pregnancies as weW'"; others have not 
found the test to be helpful in the clinically normal pa-
tient.·'? 
A clinical study was undertaken at the University of 
Iowa College of Medicine to determine whether hPL 
determinations are beneficial. The questions asked 
were: 1) Would routine antepartum hPL testing im-
prove perinatal results? 2) In clinically normal preg-
nancies would low hPL values effectively predict ad-
verse perinatal outcome? and 3) In clinically abnormal 
pregnancies would hPL testing provide information re-
garding perinatal outcome additional to that provided 
by current clinical and laboratory fetal surveillance? 
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Materials and Methods 
Volunteers from the high-risk and routine antepartum 
clinics were enrolled in the study from September 
1976 through June 1977. The only entry requirements 
were the presence of a living fetus and the absence of 
labor. At each antepartum visit from 34 weeks' gesta-
tion until delivery, a serum sample was obtained 
which was analyzed in duplicate for hPL by radioim-
munoassay using a standard commercial kit (New 
England Nuclear). Hospitalized patients had samples 
obtained weekly. 
So that obstetric management would not be influ-
enced by the serum hPL levels, hPL results were not 
reported. 
Following delivery, data sheets were completed us-
ing information from the hospital records of the 
mothers and newborns. Demographic data, identified 
risk factors, fetal surveillance test results, neonatal 
outcome data, and hPL values were recorded and sub-
sequently transferred to magnetic tape for computer 
analysis. 
Eight hundred six patients with at least 1 hPL deter-
mination delivered at University Hospitals. They and 
their 818 offspring (12 sets of twins) form the study 
population. 
Patients were categorized as follows. Groups 1 and 2 
consisted of patients whose pregnancies were defined 
as being at risk prior to labor because 1 or more of the 
following events had occurred: antepartum admission 
to the hospital, antepartum fetal heart rate (FHR) test-
ihg, urinary estrogen determination, or amniocentesis 
for fetal maturity testing and/or Il OD (optical den-
sity) 450 nm determination. Risk patients were placed 
in group 1 if they spontaneously went into labor (de-
spite their risk status, the clinical opinion apparently 
was that induction of labor was not required in these 
patients). Risk patients were assigned to group 2 if de-
livery was effected because of concern for the mother 
and/or fetus. In these patients induction of labor was 
carried out or cesarean sections were performed be-
fore labor had begun. Patients in group 3 were not 
considered to be at risk prior to labor. They were not 
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admitted to the hospital prior to labor, nor did they 
undergo antepartum FHR testing, urinary estrogen as-
says, or third-trimester amniocenteses. Some of these 
group 3 patients may have been high risk because of 
maternal age, socioeconomic status, or other factors, 
but the specific clinical and laboratory measures gen-
erally undertaken in pregnancies we consider to be at 
risk were absent. It should be emphasized that these 
operational definitions of groups 1-3 were established 
at the beginning of the study, and the assignment of a 
particular patient to a particular group was indepen-
dent of her serum hPL levels or the perinatal outcome. 
Adverse outcome variables of interest were peri-
natal death, intrauterine growth retardation (IOCR), 
congenital anomalies, meconium-stained amniotic 
fluid, FHR abnormalities in labor, fetal acidosis (pH < 
7.25) in labor, 5-minute Apgar score < 8, and the need 
for immediate neonatal resuscitation. Although the 
significance of meconium-stained amniotic fluid re-
mains controversial, it was selected as an adverse out-
come variable because it has been included as such in 
previous hPL studies. 5 ,b 
If there was a discrepancy between the clinical esti-
mate of gestational length and that suggested by phys-
ical examination of the newborn, the latter was chosen 
as indicating gestational age. Appropriateness of birth 
weight for gestational age was determined from the 
Colorado growth chart.& 
Low hPLs were defined as those values within the 
approximate 2~ percentile for each week of gestation 
(34-43 weeks) in 404 normal pregnancies. These 404 
patients were in group 3 (not at risk) and delivered liv-
ing singleton fetuses weighing from 2500 to 4000 g 
who had 5-minute Apgar scores 2:8 and who required 
no resuscitation. A patient was placed in the low hPL 
category if any single value was low. 
The study patients were categorized as having nor-
mal or low hPL levels. The outcome variables were 
compared for patients having normal or low hPL mea-
surements for the study population as a whole, indi-
vidually for groups 1-3, and for separate risk factors 
in groups I and 2. Fisher~s exact test was employed to 
determine the statistical significance of the differences 
observed. 
Results 
This study focuses on perinatal outcome. Details of 
the study populatibn and certain physiologic and 
pathophysiologic hPL relationships are the subjects of 
a separate report: 
Seven hundred seventy-two babies (94%) were de-
livered of mothers with normal serum hPL values; 46 
babies (6%) were delivered of mothers with low serum 
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hPL values. Table I compares the low and normal hPL 
groups in terms of the prt'sence or absence of the sPe-
cific adverse outcome variables. The figures in paren-
theses represent percentages within each column for 
each variable. 
Perinatal Deaths 
None of the 9 perinatal deaths occurred in patients 
with low hPL levels. There were 4 fetal deaths (2 of 
unknown cause in clinically normal patients; I fetus in 
a twin pregnancy; I growth-retarded fetus in a patient 
with hypertension). Five babies died neonatally (I fol-
lowing severe asphyxia secondary to premature sepa-
ration of the placenta; I set of twins because of pre-
sumed coxsackievirus infection; 2 secondary to cardiac 
anomalies). 
IUGR 
In the 10w-hPL group, 7% were growth retarded, ver-
sus 2% in the normal-hPL group (Table 1). The appar-
ently increased tendency for the 10w-hPL group to be 
associated with growth-retarded babies is not statisti-
cally significant. Furthermore, 93% of the babies deliv-
ered of women with low hPL values were not growth-
retarded, and the 10w-hPL group accounted for only 
17% of the growth-retarded babies in the study. 
Congenital Anomalies 
There was no difference between the low- and nor-
mal-hPL groups in this category. 
Meconium Staining of the Amniotic Fluid 
Again, no difference was noted. Only 6% of the babies 
with meconium-stained amniotic fluid were in the 
10w-hPL group. 
Abnormal FHR 
Fetal heart rate abnormalities in labor were recorded 
in 141 cases. There was no significant difference in dis-
tribution between the low- and normal-hPL groups. 
The 10w-hPL group accounted for 7% of the fetuses 
with FHR abnormalities. 
Fetal Addosis 
Scalp blood pH determinations were performed on 93 
fetuses. None of the 17 acidotic fetuses (pH < 7.25) 
were in the 10w-hPL group. 
Low 5-Minute Apgar Scores 
Infants with low 5-minute Apgar scores «8) occurred 
with equal frequency (7%) in the low- and normal-hPL 
































Table 1. Correlation of Adverse Perinatal Outcome Variables with hPL Values for Entire Study Population 
hPL 
Variable Low Nonnal Total 
Perinatal death 0 (0) 9 (1) 9 (1) 
No perinatal dl!ath 46 (100) 763 (99) 809 (99) 
Total 46 (100) 772 (100) 818 (100) 
IUGR 3 (7) 15 (2) 18 (2) 
NolUGR 43 (93) 757 (98) 800 (98) 
Total 46 (100) 772 (100) 818 (100) 
Anomaly 1 (2) 16 (2) 17 (2) 
No anomaly 45 (98) 756 (98) 801 (98) 
Total 46 (100) 772 (100) 818 (100) 
Meconium noted 8 (17) 117 (15) 125 (15) 
Meconium not noted 38 (83) 665 (85) 693 (85) 
Total 46 (100) 772 (100) 818 (100) 
Abnonnal FHR 10 (22) 131 (17) 141 (17) 
FHR nonnal 36 (78) 641 (83) 677 (83) 
Total 46 (100) 772 (100) 818 (100) 
pH low « 7.25) 0 (0) 17 (20) 17 (18) 
pH nonnal (2 7.25) 8 (100) 68 (80) 76 (82) 
Total 8 (100) 85 (100) 93' (100) 
5-minute Apgar score < 8 3 (7) 51 (7) 54 (7) 
5-minute Apgar score 2 8 43 (93) 721 (93) 764 (93) 
Total 46 (100) 772 (100) 818 (100) 
Resuscitation needed 8 (17) 158 (20) 166 (20) 
Ressuscitation not needed 38 (83) 614 (80) 652 (80) 
Total 46 (100) 772 (100) 818 (100) 
Vascular resuscitation needed 1 (2) 24 (3) 25 (3) 
Vascular resuscitation not needed 45 (98) 748 (97) 793 (97) 
Total 46 (100) 772 (100) 818 (100) 
P> 0.10 for all variables. 
Figures in parentheses are column percentages for each variable. 
hPL = Human placental lactogen; IUGR == intrauterine growth retardation; FHR = fetal heart rate . 
• Ninety-three fetuses had fetal blood sampling. 
groups. Because I-minute Apgar scores were not en-
tered on our data sheets and because with early effec-
tive resuscitation a depressed baby at birth might have 
a high 5-minute score, the need for and type of neo-
natal resuscitation were also evaluated. 
Need for Neonatal Resuscitation 
Only 5% of the 166 babies requiring resuscitation were 
in the low-hPL group. 
Need fQr Vascular Resuscitation 
Twenty-five babies were depressed enough at birth to 
require vascular resuscitation (sodium bicarbonate 
and/or plasma protein) in addition to oxygen. The fre-
quency of infants in the low- and normal-hPL groups 
did not differ. 
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For the study population as a whole, assignment to 
the 10w-hPL group was without predictive value con-
cerning the adverse outcome variables that were stud-
ied. The frequency of adverse outcome was the same 
in the low- and nOrn1al-hPL groups; a large majority in 
the 10w-hPL group was without each of the adverse 
outcome variables evaluated. 
Separate evaluation of groups 1-3 gave similar neg-
ative results. Group 3 (not at risk antepartum) con-
sisted of 576 babies. Twenty-eight (5%) infants were 
delivered of mothers with low hPL levels. The low-
hPL group had either no association or a lower fre-
quency of association, with 5 of the adverse outcome 
variables (perinatal death, congenital anomalies, fetal 
acidosis, the need for resuscitation, and the need for 
vascular resuscitation) compared with the normal-hPL 
group (N = 518). Data for the other 4 variables are 
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Table 2. Correlation of Adverse Perinatal Outcome Variables with hPL Values in Group 3* 
hPL 
Variable Low Normal Total 
HJGR 1 (4) 8 (1) 9 (2) 
NolUGR 27 (96) 540 (99) 567 (98) 
Total 28 (100) 548 (100) 576 (100) 
Meconium noted 6 (21) 90 (16) 96 (17) 
Meconium not noted 22 (79) 458 (84) 4SO (83) 
Total 28 (100) 548 (100) 576 (100) 
Abnonnal FHR 5 (18) 74 (14) 79 (14) 
FHRnonnal 23 (82) 474 (87) 497 (86) 
Total 28 (100) 548 (100) 576 (100) 
5-minute Apgar score < 8 3 (11) 32 (6) 35 (6) 
5-minute Apgar score <!: 8 25 (89) 516 (94) 541 (94) 
Total 28 (100) 548 (100) 576 (100) 
P > 0.10 for all variables. 
Figures in parentheses are column percentages for each variable. 
hPL = Human placental lactogen; IUGR = intrauterine growth retardation; FHR = fetal heart rate . 
.. Group 3 = Patients not considered to be at risk prior to labor. 
shown in Table 2. Again, no statistically significant 
differences were observed between the low- and nor-
mal-hPL groups. 
Two hundred forty-two babies were delivered of 
mothers in the at-risk groups 1 and 2. Mothers were 
assigned to the risk groups based on medical (eg, dia-
betes mellitus and chronic hypertension) and obstetric 
[eg, premature rupture of the membranes (PROM) 
without labor, third-trimester bleeding, and pre-
eclampsia] factors. 
One hundred forty-four babies were delivered of 
mothers in group 1. Although increased risk explained 
certain management steps (eg, antepartum FHR test-
ing) not taken in group 3 patients, no indicated effec-
ting of delivery was undertaken. Ten of these babies 
(7%) were delivered of mothers with low hPL levels. 
This low.,.hPL group had no association or a lower fre-
quency of association with 8 of the 9 adverse oqtcome 
variables than did the normal-hPL group (N = 134). 
Data for the remaining variable (meconium-stained 
amniotic fluid) showed no real differences (Table 3). 
There were 98 babies delivered to mothers in group 
2. These at-risk patients had delivery effected by in-
dicated induction of labor or by cesarean section per-
formed before labor had begun. Eight of these babies 
(8%) were delivered of mothers with low hPL levels. 
This low-hPL group had no association or a lower fre-
quency of association with 4 of the 9 adverse outcome 
variables (perinatal death, meconium-stained amniotic 
fluid, fetal acidosis, and low 5-minute Apgar score) 
than did the normal-hPL group (N == 90). The 5 re-
maining variables are considered in Table 4. In group 
2 patients with low hPL levels there is a suggestion of 
an increased rate of IUGR (statistically significant) and 
FHR abnormalities (not statistically significant) when 
compared with group 2 patients with normal hPL lev-
els, although the small numbers limit interpretation. 
The 11 low-hPL adverse variable entries in Table 4 
represent 6 patients (3 with hypertension, 1 with renal 
disease and suspected IUGR, and 2 with PROM with-
out labor). Five of the 6 patients had had amniotic 
fluid maturity testing and/or antepartum fetal well-
Table 3. Meconium-Stained Amniotic Fluid as Related to hPL Values (Group 1) 
Meconium noted 
Meconium not noted 
Total 




Figures in parentheses are column percentages. 
hPL = Human placental lactogen. 
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• being testing. All 6 patients were admitted to the hos-
pital prior to labor and had indicated inductions of la-
bor. Their doctors made their management decisions 
without knowledge of the 10w-hPL test results. 
Analysis of outcome by specific risk factors for the 
low- and normal-hPL groups did not demonstrate hPL 
testing to be of predictive value. 
Discussion 
In a recent review, Spellacy summarized the literature 
regarding control factors for hPL and clinical studies 
of hPL as a placental function test.'o It had been noted 
previously that hypertensive women who sustained 
intrauterine fetal deaths tended to have low hPL levels, 
and it was suggested that serum hPL might serve as a 
test of placental function. It A prospective study of a 
high-risk clinic population (both hypertensive and 
normotensive) resulted in fewer perinatal deaths if low 
hPL results were reported than if they were not.' Yli-
korkala found that low hPL levels were associated 
with fetal distress and/or IUGR in a variety of preg-
nancy complications.2 
Following these earlier observations, the potential 
usefulness of hPL testing as an adjunct in obstetric 
management was extended from use in hypertensive 
patients to use in general high-risk patients, and fi-
nally, with the studies of Letchworth and Chard~ and 
England et at 6 to use as a general screening test in nor-
mal pregnancies. 
Other workers have been less enthusiastic. They 
have found the test to be less helpful in predicting 
perinatal outcome or altering clinical management in 
high-risk or normal patientsY 
In a separate report based on these 806 women with 
normal and abnormal pregnancies, we have demon-
strated a significant correlation between hPL levels 
and birth weight and have noted mean hPL differences 
in conditions where large or small placentas are antici-
pated.9 In the present report, however, we are unable 
to demonstrate a relationship between Jow hPL values 
and adverse perinatal outcome. Why? 
Placental weights are correlated in a positive man-
ner with serum hPL levels. The placenta in patients 
with hypertension or with growth-retarded fetuses 
tends to be small. Patients with these conditions are 
predisposed to adverse perinatal outcome. Therefore, 
it is not surprising that some patients with these en-
tities and low hPL levels have problems. This associa-
tion does not, however, establish that serum hPL can 
serve as a clinically useful marker of placental func-
tion or as an effective predictor of perinatal outcome. 
The production of this hormone is related to placental 
size, but considerable variation exists. Although the 
mean hPL level of patients with growth-retarded fe-
tuses is significantly lower than that of patients whose 
Table 4. Correlation of Adverse Perinatal Outcome Variables with hPL Values (Group 2) 
hPL 
Variable Low Nonnal Total 
IUGR 2 (25) 1 (1) 3 (3) 
NolUGR 6 (75) 89 (99) 95 (97) 
Total 8 (100) 90 (100) 98 (100) 
P<0.05 
A.nomaly 1 (13) 0 (0) 1 (1) 
No anomaly 7 (88) 90 (100) 97 (99) 
Total 8 (100) 90 (100) 98 (100) 
P=0.08 
A.bnonnal FHR 5 (63) 30 (33) 35 (36) 
FHRnonnal 3 (38) 60 (67) 63 (64) 
Total 8 (100) 90 (100) 98 (100) 
p .. 0.10 
Resuscitation needed 2 (25) 17 (19) 19 (19) 
Resuscitation not needed 6 (75) 73 (81) 79 (81) 
Total 8 (100) 90 (100) 98 (100) 
P=0.82 
Vascular resuscitation needed 1 (13) 3 (3) 4 (4) 
Vascular resuscitation not needed 7 (88) 87 (97) 94 (96) 
Total 8 (100) 90 (100) 98 (100) 
P=O.97 
Figures in parentheses are column percentages for each yariable. 
hPL '" Human placental lactogen; IUGR '" intrauterine growth retardation; FHR - fetal heart rate. 







fetuses are not growth retarded/ the overlap between 
the 2 groups limits the predictive value of the test. 
Ninety-three percent of our patients with low hPL lev-
els gave birth to babies who were not growth retarded. 
Furthermore, the important transport functions of the 
placenta may be independent of the placenta's ability 
to produce hPL. Blood levels of another placental hor-
mone, progesterone, have not been helpful in clinical 
obstetric management." 
It should be emphasized that those group 2 patients 
in this study with low hPL levels and an apparently in-
creased frequency of certain adverse outcome vari-
ables had been identified clinically without knowledge 
of the hPL test results. Therefore, in the one subset of 
the study population where there may be a relation-
ship between low hPL levels and adverse outcome 
(group 2), the test apparently would not have provided 
additional information. The decision to deliver these 
patients had already been made. 
In the hands of the authors routine hPL screening 
would result in many false positives, ie, low hPL levels 
in patients who did not have adverse perinatal out-
come. The increased concern for patients with low hPL 
levels might result in additional expense in fetal sur-
veillance and possibly in iatrogenic prematurity as 
well. 'In this study, low hPL levels were defined as 
those within the approximate 2~ percentile of carefully 
characterized normal patients. This is consistent with 
levels chosen by other authors .of large series.l •U Al-
though a less rigidly selected 10w-hPL group would in-
clude more patients with adverse perinatal outcome, 
the problem with false positives would likewise be ex-
pected to be greater. 
Possible explanations for our failure to find low hPL 
levels to be of predictive value may relate to differ-
ences in our patient population or in our clinical man-
agement. For example, patients with preeclampsia who 
do not respond rapidly to in-hospital treatment on our 
service are generally delivered. 
This study was designed to evaluate the clinical util-
ity of hPL determinations in late pregnancy. Our data 
do not support the use of hPL testing as a routine 
screening procedure to improve perinatal outcome. 
Low hPL values did not effectively predict adverse 
perinatal outcome in clinically normal patients. In 
clinically abnormal pregnancies our tentative con-
. clusion is that hPL determinations did not provide in-
formation regarding perinatal outcome over and above 
that provided by our current clinical and laboratory 
fetal surveillance. A definite statement cannot be 
made, however, because the numbers of patients in 
specific risk categories (eg, chronic hypertension) are 
not large enough to permit meaningful evaluation. 
Others are encouraged to study hPL testing in their 
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high-risk patient populations on a blind or prospec_ 
tively controlled basis. The value of the test, if any ex-
ists, must be in providing additional information to 
that obtained by the careful· clinician using the cur-
rently available diagnostic tools. 
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